Advertisement

The journal of mental health administration

, Volume 12, Issue 2, pp 22–27 | Cite as

Tardive Dyskinesia: Facts the mental health administrator may not know

  • Kenneth M. Slaw
  • John E. Kalachnik
Article
  • 12 Downloads

Conclusion

Hospitals and other health care organizations are under constant pressure to meet standards which ensure patient progress and welfare. It is their ethical and professional responsibility to do so. Should a hospital fail to meet these standards, legal entanglements will occur.

In general, the health care community makes a sincere attempt to meet its ethical obligations. When a hospital does not, however, it may be that methods and procedures to meet the standard of care are not specified or do not exist.

The purpose of this article is to communicate to healthcare administrators, especially those working in the mental health field, that
  • ▪ Tardive dyskinesia is a very real problem that must be resolved soon.

  • ▪ There is a legal mandate which demands hospitals to systematically monitor for behavioral side effects due to neuroleptic medications.

  • ▪ The price for failing to monitor for TD may cost the hospital and physicians millions of dollars.

  • ▪ There is a cost-effective, efficient and reliable manner in which to manage this problem.

The solution calls for a comprehensive dyskinesia monitoring and cvaluation system.

Keywords

Tardive Dyskinesia Hospital Administrator Mental Health Field Task Force Report Neuroleptic Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Clites v. Iowa, No. 46274 (Iowa District Court for Pottawattamic County, filed August 7, 1980).Clites v. Iowa, 2-04-2-65599 (Iowa Court of Appeals, filed June 29, 1982).Google Scholar
  2. 2.
    Faigenbaum v. Cohen, No. 79-904-736-NM (Wayne County Michigan, filed February 14, 1979).Google Scholar
  3. 3.
    Headley v. Hanneken is reported as a summary in “Doctor Continues Use of Drug in Spite of Side Effects: Tardive Dyskinesia; S315,000 Recovery as a Result of Verdict and Settlement.”Verdict, 6, 61–62, 1984.Google Scholar
  4. 4.
    Hedin v.U.S.A., No. 5-83 CIV 3 (United States District Court, District of Minnesota, Fifth Division, filed September 4, 1984).Google Scholar
  5. 5.
    Lesser v. Farbe, Synopsis reported in: Patterson, J.D. & Robinson, R.E. (Eds.),Drugs in Litigations: Damage Awards Involving Prescription Drugs (2nd Ed). Indianapolis: Allen Smith Co., 1982.Google Scholar
  6. 6.
    Collins v. Cushner, id..Google Scholar
  7. 7.
    C.T. Gualtieri and R.L. Sprague, “Preventing Tardive Dyskinesia and Preventing Tardive Dyskinesia Litigation,”Psychopharmacology Bulletin, 20, 3, 346–348, 1984.PubMedGoogle Scholar
  8. 8.
    American Psychiatric Association Task Force Report on Late Neurological Effects of Antipsychotic Drugs,Tardive Dyskinesia. Task Force Report 18. Washington D.C.: American Psychiatric Association, 1979.Google Scholar
  9. 9.
    R.J. Baldessarini and D. Tarsey, “Tardive Dyskinesia.” In M.A. Kipton, A. Di-Mascio, & K.F. Killam (Eds.),Psychopharmacology: A Generation of Progress, pp. 993–1004, New York, NY: Raven Press, 1978.Google Scholar
  10. 10.
    J.E. Kalachnik, et al., “Persistent Tardive Dyskinesia in Randomly Assigned Neuroleptic History Groups: Preliminary Results.”Psychopharmacology Bulletin, in press.Google Scholar
  11. 11.
    D.V. Jeste and R.J. Wyatt,Understanding and Treating Tardive Dyskinesia. New York, NY. Guilford Press, 1982. J.E. Kalachnik, “Tardive Dyskinesia,”Minnesota Pharmacist, 37, 6–13, 1983b.Google Scholar
  12. 12.
    G.M. Simpson, E.J. Pi, and J.J. Sramek, “Management of Tardive Dyskinesia: Current Update,”Drugs, 23, 381–393, 1982.PubMedCrossRefGoogle Scholar
  13. 13.
    G.M. Simpson, et al., “A Rating Scale for Tar Tardive Dyskinesia,”Psychopharmacology, 64, 171–179, 1979.PubMedCrossRefGoogle Scholar
  14. 14.
    R.C. Smith, et al., “A Rating Scale for Tar-dive Dyskinesia and Parkinsonian Symptoms,”Psychopharmacology Bulletin, 19, 266–276, 1983.PubMedGoogle Scholar
  15. 15.
    J.M. Kane and J.M. Smith, “Tardive Dyskinesia: Prevalence and Risk Factors, 1959–1979.”Archives of General Psychiatry, 39, 473–481, 1982.PubMedGoogle Scholar
  16. 16.
    G.D. Mellinger and M.B. Balter, “Prevalence and Patterns of Use of Psychotropic Drugs: Results from a 1979 National Survey of American Adults.” In G. Tognoni, C. Bellantuono & M. Lader (Eds.),Epidemiological Impact of. Psychotropic Drugs, Amsterdam; Elservier-North Holland, Biomedical Press, 1981. Sandoz Pharmaceuticals.Tardive Dyskinesia: The Key Issue in Psychiatric Practice Today (MEL-283). Aust Hanover, NJ, 1982.Google Scholar
  17. 17.
    P.M. Danzon, “An Economic Analysis of the Medical Malpractice System,”Behavioral Science and the Law, 1, 39–54, 1983.CrossRefGoogle Scholar
  18. 18.
    Nina Schooler et al., Psychopharmacology Branch, National Institute of Mental Health, Rockville, MD.Google Scholar
  19. 19.
    George Simpson, Professor of Psychiatry, University of Southern California, Los Angeles, CA. Also Director, USC-MSH Psychopharmacology Service, Metropolitan State Hospital, Norwalk, CA.Google Scholar
  20. 20.
    Robert Smith, Chief Behavioral Neurochemistry, Texas Research Institute of Mental Sciences, Houston. Also Research Assistant Professor of Pharmacology, Baylor College of Medicine, Houston, TX.Google Scholar
  21. 21.
    Jes Gerlach, Section Hans Hospital, Department H, Rosklide, Denmark.Google Scholar
  22. 22.
    R.J. Sprague, Institute of Child Behavior and Development. University of Illinois, Champaign, IL.Google Scholar
  23. 23.
    J.E. Kalachnik, State of Minnesota, Cambridge State Hospital, Cambridge, MN.Google Scholar
  24. 24.
    David M. Englehardt, Professor of Psychiatry, Department of Psychiatry/psychopharmacology, Downstate Medical Center, SUNY, 450 Clarkson Avenue, Brooklyn, New York, 11203.Google Scholar
  25. 25.
    Minnesota facilities: Anoka, Brainird, Cambridge, Fergus Falls, Moose Lake, St. Peter and Willmar; Colorado: Wheatridge; Illinois: McFarland, Meyer, Jacksonville, Lincoln, and Dwight; Kansas: Norton; Michigan: Mt. Pleasant; Virginia: Southeastern.Google Scholar

Copyright information

© Association of Behavioral Healthcare Management 1985

Authors and Affiliations

  • Kenneth M. Slaw
  • John E. Kalachnik

There are no affiliations available

Personalised recommendations